Analytical

As cell therapy trials advance, creating a simplified, efficient, and harmonized supply chain has never been more significant to prepare for evolving your supply chain to stay ahead of the accelerations of trials and facilitate more patients receiving cell therapy treatment safely in the most optimized and cost-effective way. Uniting supply chain and clinical operations experts, this summit gave a unique opportunity to collaborate with the cross-functional roles supporting supply chain management to ensure alignment between teams.

As momentum continues to build for the cell therapy industry, process development looms as a huge potential bottleneck to overcome. The inaugural Process Development for Cell Therapies Summit will give you unprecedented access to an industry melting pot of process development tools and experience to drive down cost of goods, maximize scalability and achieve regulatory compliance.Join your peers who will all be gathering to learn how to identify and plug platform gaps for automation, global scale-out, faster phase development, increased affordability, and more!With 20+ case studies being presented, you will come away with tried and tested strategies informed by industry leaders such as BMS, Kite, Lyell Immunopharma, and Immatics Biotechnologies. There is no other event of this kind which is focused specifically on Process Development for Cell Therapy, delivering case studies to provide actionable insights.Now is the time to gather with the industry gurus to unpick shared challenges in process development and share best practices to de-silo the industry and bring better therapies to patients faster.

Hundreds of clinical trials using AAV are underway, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline, the need to administer high doses, the clinical holds placed on gene therapy trials, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that’s fit for purpose! In this setting, the inaugural Optimizing AAV Safety Summit is bringing together key leaders focussed specifically on solving AAV safety challenges across toxicology, pharmacology, non-clinical study leads, clinical development safety specialists and bioanalysis innovators to gain insights on optimizing AAV safety processes and benefit-risk analysis to shorten timelines and prevent potential delays.Join us in Boston alongside key biotech and pharma leaders from the likes of Spark Therapeutics, Ask Bio, Eli Lilly, Takeda, and more in the AAV space who are prioritizing the development of safe and effective genetic therapies, learn how clinical safety signals have changed how companies are approaching their pipeline progression, and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development.

The 2nd Annual Next Generation Gene Therapy Vectors Summit is dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors.Industry pioneers from cutting edge biopharma and world-leading academic vectorology groups including Voyager Therapeutics, Spark Therapeutics, Dyno Therapeutics, Chameleon Biosciences, BioMarin and more will share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely. Spanning a range of delivery approaches from cutting-edge AAV capsid optimisation, utilising lenti and other viral vectors, to innovative non-viral gene therapy approaches, this comprehensive event will enable you to reduce immunogenicity, improve tissue targeting, simplify manufacturing and enhance the safety profile of your approach. Everything in gene therapy starts with delivery, so join this definitive, niche conference to delve into the details of vector design, engineering and optimization case studies, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before.

The two-day conference and one-day exhibition provides the perfect venue for easy, informal discussions for manufacturing, packaging, laboratory services and more!

The field of food allergy therapeutics is continuing to boom as companies flood the news with fresh IND clearances and clinical readouts. The race to market for the next food allergy therapy is well and truly on, but access to funding and large patient cohorts, along with the need for novel IgE biomarkers and better diagnostics (to name a few challenges) are holding drug developers back from even faster progress. The 2nd Next-Generation Food Allergy Drug Development Summit is reuniting this December as the only industry-focused meeting dedicated to unveiling the complexities of food allergies with novel oral immunotherapies, antibody-based therapeutics and microbiome-based approaches to accelerate ground-breaking treatments for the ever-increasing unmet medical need.

“The Macrophage-directed Therapies Summit is returning for the 4th year, back to Boston – and continues to be the leading industry-focused forum uniting this emerging community of over 100 leaders to review cutting-edge advances in the discovery, preclinical, translational, and clinical development of macrophage-directed therapies.Covering discovery to the clinic and a brand-new Biomarkers Bootcamp, the summit is returning with two tracks of content.Join the likes of Gilead Sciences, Pionyr Immunotherapeutics, KAHR Medical, Codiak BioSciences, Ichnos Sciences, and Enlivex Therapeutics Ltd, and receive the latest updates on clinical progress, novel approaches, and targets to broaden the spectrum of macrophage targeting. With continuing growth in the macrophage space, delve into:
CD47 targeting and other ‘don’t eat me’ signals
Safety concerns due to model translatability and dosing
Optimal combination or monotherapy discovery
Learn from our expert speaker faculty, who will be sharing more exclusive new or unpublished insights than ever before.”

Connect with iPSC trailblazers, including Century Therapeutics, Sana Biotechnology and Novo Nordisk, to create best-in-class iPSC-derived cell therapies for immuno-oncology and regenerative medicine.

The Innate Killer Summit returns for its 7th year as the industry-defining forum advancing the field to achieve clinical success. Spanning the current drug development landscape, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies.Join over 200 experts to characterize and contrast cell sources, supercharge combinations, optimize CMC workflows, examine expansion protocols for high-quality products at scale, and move the field towards persistent, scalable, and cost-effective innate immune cell therapies. Promising unpublished data, interactive discussion, and engaging networking opportunities join the 7th Innate Killer Summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.

The momentum of innate immune cell R&D is growing exponentially to harness innate immune responses in oncology, realise scaled allogeneic manufacturing, and drive commercial stage-products. Now is the time to gather this burgeoning community at the crucible of innovation: in Europe.The Innate Killer Summit Europe gathers 80+ key European Gamma Delta T, NK, and Macrophage developers in October to chase the holy grail of efficacious, off-the-shelf, solid tumour immunotherapies through innate cell targeting and engineering.The Innate Killer Summit Europe gathers 80+ key European Gamma Delta T, NK, and Macrophage developers in October to chase the holy grail of efficacious, off-the-shelf, solid tumour immunotherapies through innate cell targeting and engineering.